chloroquine has been researched along with lumefantrine in 79 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (2.53) | 18.2507 |
| 2000's | 26 (32.91) | 29.6817 |
| 2010's | 42 (53.16) | 24.3611 |
| 2020's | 9 (11.39) | 2.80 |
| Authors | Studies |
|---|---|
| Jomaa, H; Kettler, K; Schlitzer, M; Wiesner, J | 1 |
| Jomaa, H; Kettler, K; Ortmann, R; Sakowski, J; Schlitzer, M; Wiesner, J | 1 |
| Fucik, K; Jomaa, H; Kettler, K; Ortmann, R; Sakowski, J; Schlitzer, M; Wiesner, J | 1 |
| Jomaa, H; Mitsch, A; Schlitzer, M; Wiesner, J | 1 |
| Du, LP; Li, MY; Tsai, KC; Xia, L; You, QD | 1 |
| Anstey, NM; Brockman, A; Chalfein, F; Cheng, Q; Kenangalem, E; Piera, K; Prasetyorini, B; Prayoga, P; Price, RN; Russell, B; Sugiarto, P; Suwanarusk, R; Tjitra, E | 1 |
| Adrián, F; Anderson, P; Brinker, A; Caldwell, JS; Chatterjee, A; Gray, NS; Henson, K; Janes, J; Kato, N; Kuhen, K; Matzen, JT; McNamara, C; Nagle, A; Nam, TG; Plouffe, D; Schultz, PG; Trager, R; Winzeler, EA; Yan, SF; Zhou, Y | 1 |
| Anstey, NM; Chalfien, F; Hasugian, AR; Kenangalem, E; Marfurt, J; Penttinen, PM; Piera, KA; Price, RN; Purba, HL; Ratcliff, A; Russell, B; Siswantoro, H; Tjitra, E; Wuwung, RM | 1 |
| Almeras, L; Amalvict, R; Baret, E; Briolant, S; Fusaï, T; Henry, M; Parquet, V; Pradines, B; Rogier, C; Torrentino-Madamet, M | 1 |
| Masseno, V; Muriithi, S; Nzila, A | 1 |
| Abdirahman, A; Borrmann, S; Bull, P; Diriye, A; Kiara, SM; Marsh, K; Mwai, L; Nzila, A; Pole, L; Rippert, A | 1 |
| Greenhouse, B; Joloba, M; Kiggundu, M; Nanyunja, S; Nsobya, SL; Rosenthal, PJ | 1 |
| Borrmann, S; Kiara, SM; Mwai, L; Nzila, A; Ochola, LI; Ohuma, E; Okombo, J; Pole, L; Rono, J | 1 |
| Sen, S; Sinha, N | 1 |
| Batty, KT; Bolitho, EM; Davis, TM; Fox, SA; Murray, PE; Whittell, LR; Wong, RP | 1 |
| Barnes, SW; Bonamy, GM; Bopp, SE; Borboa, R; Bright, AT; Chatterjee, A; Che, J; Cohen, S; Dharia, NV; Diagana, TT; Fidock, DA; Froissard, P; Gagaring, K; Gettayacamin, M; Glynne, RJ; Gordon, P; Groessl, T; Kato, N; Kuhen, KL; Lee, MC; Mazier, D; McNamara, CW; Meister, S; Nagle, A; Nam, TG; Plouffe, DM; Richmond, W; Roland, J; Rottmann, M; Sattabongkot, J; Schultz, PG; Tuntland, T; Walker, JR; Winzeler, EA; Wu, T; Zhou, B; Zhou, Y | 1 |
| Biamonte, MA; Le Roch, KG; Wanner, J | 1 |
| Barteselli, A; Basilico, N; Mommo, D; Parapini, S; Sparatore, A | 1 |
| Avery, VM; Buchholz, M; Delves, MJ; Duffy, S; Fischli, C; Held, J; Knaab, TC; Kuna, K; Kurz, T; Lehmann, U; Leven, M; Lungerich, B; Meister, S; Meitzner, D; Mordmüller, B; Stahlke, P; Winzeler, EA; Wittlin, S | 1 |
| Bane, CE; Black, C; Butler, K; Caridha, D; Cooper, RA; Dodean, RA; Gaona, H; Gaynor-Ohnstad, L; Huezo, SJ; Kancharla, P; Kelly, JX; Kreishman-Deitrick, M; Leed, SE; Li, Q; Li, Y; Lin, H; Luong, TL; Marcsisin, S; Melendez, V; Nolan, C; Olmeda, R; Potter, B; Pou, S; Rasmussen, SA; Read, L; Riscoe, MK; Roncal, N; Sciotti, RJ; Smilkstein, MJ; Sousa, J; Stephens, MT; Tan, JC; Vesely, B; Vuong, C; Winter, RW; Xie, L; Zeng, Q; Zhang, J; Zhang, P | 1 |
| Cheong, SL; Ng, CH; Tibon, NS | 1 |
| Bane, CE; Bayles, BR; Black, C; Butler, K; Caridha, D; Ceja, FG; Cooper, RA; Dodean, RA; Gaona, H; Gaynor-Ohnstad, L; Kancharla, P; Kelly, JX; Kreishman-Deitrick, M; Leed, SE; Li, Q; Li, Y; Lin, H; Luong, TL; Marcsisin, S; Melendez, V; Mu, J; Nolan, C; Olmeda, R; Potter, B; Pou, S; Pybus, B; Rasmussen, SA; Read, L; Reynolds, KA; Riscoe, MK; Roncal, N; Rosenthal, PJ; Sciotti, RJ; Smilkstein, MJ; Sousa, J; Tumwebaze, PK; Vesely, B; Vuong, C; Xie, L; Zeng, Q; Zhang, J; Zhang, P | 1 |
| Abdulla, S; Beck, HP; Gathmann, I; Hatz, C; Kibatala, P; Mull, R; Royce, C; Schellenberg, D; Tanner, M | 1 |
| Björkman, A; Hassan Alin, M; Wernsdorfer, WH | 1 |
| Stingl, P | 1 |
| Annerberg, A; Barends, M; Keola, S; Khanthavong, M; Lindegårdh, N; Mayxay, M; Newton, PN; Phetsouvanh, R; Phompida, S; Pongvongsa, T; White, NJ; Yapom, R | 1 |
| Kollaritsch, H; Lux, D; Prajakwong, S; Wernsdorfer, G; Wernsdorfer, WH | 1 |
| Bangali, AM; Barends, M; Das, S; Faiz, AM; Kamal, M; Liem, L; Maung, UA; Peters, A; Rahman, M; Rahman, MR; van den Broek, IV | 1 |
| Garner, P; Jones, K; Taylor-Robinson, D | 1 |
| Bourée, P | 1 |
| Ahmed, ES; Elamin, SB; Elhassan, AH; Elmardi, KA; Malik, EM; Mannan, AA; Mohamed, TA; Mowien, RM | 1 |
| Anderson, T; Barends, M; Brockman, A; Jaidee, A; Mayxay, M; Nair, S; Newton, PN; Phetsouvanh, R; Phompida, S; Pongvongsa, T; Sudimack, D; White, NJ | 1 |
| Abdalli Mari, M; Ariey, F; Astafieva-Djaza, M; Gayibor, AH; Hafidhou, M; Moussa, M; Oumadi, A; Randrianarivelojosia, M; Ringwald, P; Said Ahmed, B; Said Ankili, A; Silai, R | 1 |
| Kano, S; Krudsood, S; Looareesuwan, S; Luplertlop, N; Muangnoicharoen, S; Ringwald, P; Srivilairit, S; Tangpukdee, N; Thanachartwet, V; Wilairatana, P | 1 |
| Nyunt, MM; Plowe, CV | 1 |
| Chanda, P; Hamer, DH; Olumese, P; Simon, JL; Sipilanyambe, N; Snow, RW | 1 |
| Davis, TM; Gomorrai, PS; Griffin, S; Ilett, KF; Karunajeewa, HA; Kotab, K; Lautu, D; Law, I; Lin, E; Mueller, I; Oa, O; Page-Sharp, M; Salman, S; Senn, M; Siba, P; Suano, P; Tarongka, N; Ura, A; Wong, R | 1 |
| Engl, M; Gluderer, D; Ogwang, M; Ploner, F; Ploner, M; Prugger, C; Wernsdorfer, G; Wernsdorfer, WH | 1 |
| Abiodun, O; Bell, A; Brun, R; Chollet, J; Irungu, BN; Kiboi, DM; Langat, B; Nganga, JK; Nyambati, VC; Nzila, A; Rukunga, GM; Wittlin, S | 1 |
| Oguonu, T; Okafor, HU; Shu, EN | 1 |
| Bei, ZC; Cao, WC; Wang, H; Wang, JY | 1 |
| Amalvict, R; Baret, E; Briolant, S; Charras, S; Feraud, M; Henry, M; Huyghues des Etages, E; Pascual, A; Pradines, B; Rogier, C | 1 |
| Anstey, NM; Chan, L; Donaldson, S; Frederick, C; Jelip, J; Khoo, S; Ma, G; Menon, J; Rajahram, G; William, T; Yeo, TW | 1 |
| Ensom, MH; Wilby, KJ | 1 |
| Al-Thukair, A; Nzila, A; Ohuma, E; Okombo, J | 1 |
| Arzika, I; Fandeur, T; Guillebaud, J; Issaka, M; Maazou, A; Salissou, A; Specht, S; Zamanka, H | 1 |
| Akala, HM; Andagalu, B; Bulimo, W; Cheruiyot, A; Eyase, FL; Ingasia, L; Johnson, JD; Juma, D; Kamau, E; Okudo, C; Omondi, A; Schnabel, D; Walsh, DS; Wanja, E; Waters, NC; Yeda, R | 1 |
| Akinyi, S; Alemayehu, BH; Birhanu, SG; Demeke, L; Filler, S; Green, M; Hoos, D; Hwang, J; Jima, D; Kachur, SP; Kassa, M; Malone, JL; Melaku, Z; Nettey, H; Poe, A; Reithinger, R; Tekleyohannes, SG; Udhayakumar, V | 1 |
| Anderson, TJ; Jamsen, KM; Nair, S; Nosten, F; Price, RN; Simpson, JA; White, NJ; Woodrow, C; Zaloumis, S | 1 |
| Abdi, AI; Kiara, SM; Mwai, L; Nzila, A; Ochola-Oyier, LI; Okombo, J; Pole, L; Sutherland, CJ | 1 |
| Burkholder, B; Bustos, MD; Delacollette, C; Wongsrichanalai, C | 1 |
| Cui, L; Gupta, B; Miao, J; Sun, L; Wang, Z; Xu, S; Yang, Z | 1 |
| Adam, I; Ademowo, G; Arze, C; Baliraine, FN; Berens-Riha, N; Björkman, A; Borrmann, S; Checchi, F; Dahal, P; Davis, TME; Desai, M; Dhorda, M; Djimdé, AA; Dorsey, G; El-Sayed, BB; Eshetu, T; Eyase, F; Falade, C; Faucher, JF; Fröberg, G; Gadalla, NB; Grivoyannis, A; Guérin, P; Hamour, S; Houzé, S; Johnson, J; Kamugisha, E; Kariuki, S; Kiechel, JR; Kironde, F; Kofoed, PE; LeBras, J; Malmberg, M; Mårtensson, A; Ménard, D; Moriera, C; Mwai, L; Ngasala, B; Nosten, F; Nsanzabana, C; Nsobya, SL; Nzila, A; Oguike, M; Ogutu, B; Otienoburu, SD; Ouédraogo, JB; Piola, P; Plowe, CV; Price, RN; Rombo, L; Rosenthal, PJ; Schramm, B; Sibley, CH; Somé, AF; Stepniewska, K; Sutherland, CJ; Thwing, J; Ursing, J; Venkatesan, M; Wong, RPM; Zeynudin, A; Zongo, I | 1 |
| Baret, E; Bercion, R; Camara, C; Diatta, B; Diémé, Y; Fall, B; Fall, KB; Fall, M; Mbaye, PS; Nakoulima, A; Pascual, A; Pradines, B; Wade, B; Wurtz, N | 1 |
| Jovel, IT; Kofoed, PE; Rodrigues, A; Rombo, L; Ursing, J | 1 |
| Bigira, V; Bloome, J; Byaruhanga, O; Conrad, MD; Cooper, RA; Dorsey, G; Greenhouse, B; Gut, J; Havlir, DV; Kakuru, A; Kamya, MR; Kapisi, J; Kozak, B; LeClair, N; Legac, J; Nakazibwe, C; Nsobya, SL; Okiring, J; Rosenthal, PJ; Tumwebaze, P; Walakira, A | 1 |
| Barnwell, JW; Goldman, I; Juma, E; Kariuki, S; Komino, F; Lucchi, NW; Okoth, SA; Onyona, P; Shi, YP; Udhayakumar, V; Wiegand, RE | 1 |
| Cabrera, M; Cui, L | 1 |
| Denti, P; du Plessis, LH; Govender, K; Wiesner, L | 1 |
| Amalvict, R; Benoit, N; Diatta, B; Diawara, S; Diémé, Y; Fall, B; Fall, M; Gendrot, M; Madamet, M; Nakoulima, A; Pradines, B; Wade, B; Wade, KA | 1 |
| de Jager, C; Hongoro, C; Longwe, H; Mutero, CM; Mwendera, C; Phiri, K | 1 |
| Amalvict, R; Benoit, N; Briolant, S; Diatta, B; Diawara, S; Diémé, Y; Fall, B; Fall, M; Gendrot, M; Kounta, MB; Madamet, M; Nakoulima, A; Pradines, B; Wade, B; Wade, KA | 1 |
| Gil, JP; Krishna, S | 1 |
| Byaruhanga, O; Ceja, FG; Conrad, MD; Cooper, RA; Katairo, T; Nsobya, SL; Rasmussen, SA; Rosenthal, PJ; Tumwebaze, PK | 1 |
| Affara, M; Ahmad, A; Amambua-Ngwa, A; Ceesay, S; D'Alessandro, U; El-Fatouri, F; Janha, R; Joof, F; Kolly, O; Mbye, H; Nwakanma, D; Nyang, H; Okebe, J | 1 |
| Annan, K; Ansah, C; Forkuo, AD; Gyan, B; Mancama, D; Mensah, KB; Theron, A; Wright, CW | 1 |
| Agarwal, P; Anvikar, AR; Pillai, CR; Srivastava, K | 1 |
| Bai, Y; Cao, Y; Cui, L; Deng, S; Geng, J; Li, C; Li, N; Liu, H; Ngassa Mbenda, HG; Ruan, Y; Wang, Z; Wu, Y; Xu, S; Yang, Z; Zeng, W; Zhang, J | 1 |
| Anvikar, A; Goomber, S; Mishra, N; Valecha, N; Yadav, CP | 1 |
| Fukuda, N; Hirai, M; Hombhanje, F; Ikeda, M; Mita, T; Mori, T; Sekihara, M; Tachibana, SI; Tiwara, S; Yamauchi, M; Yatsushiro, S | 1 |
| Asua, V; Conrad, MD; Dorsey, G; Kamya, MR; Kigozi, SP; Legac, J; Nsobya, SL; Rosenthal, PJ; Vinden, J | 1 |
| Abdel-Muhsin, AA; Abdelraheem, MH; Al Dhuhli, A; Al Hosni, A; Al Rubkhi, M; Al-Hamidhi, S; Babiker, HA; Bakhiet, AMA; Gadalla, A; Gismelseed, L; Kheir, A; Mukhtar, M; Naiem, A; Omer, S; Sultan, AA | 1 |
| Bah, S; Dabitao, D; Dama, S; Diakité, M; Diakité, SAS; Doumbia, S; Doumbouya, M; Guindo, MA; Keita, B; Konaté, DS; Sangaré, M; Sanogo, I; Traoré, K | 1 |
| Anywar, DA; Auma, MA; Balikagala, B; Emoto, S; Fukuda, N; Hashimoto, M; Hirai, M; Horii, T; Ikeda, M; Kataoka, M; Katuro, OT; Kimura, E; Mita, T; Mori, T; Obwoya, PS; Odongo-Aginya, EI; Ogwang, M; Opio, W; Palacpac, NMQ; Sakurai-Yatsushiro, M; Sekihara, M; Tachibana, SI; Yamauchi, M; Yatsushiro, S | 1 |
| Conrad, MD; Cooper, RA; Duvalsaint, M; Legac, J; Rosenthal, PJ; Tukwasibwe, S; Tumwebaze, PK | 1 |
| Asua, V; Aydemir, O; Bailey, JA; Bayles, BR; Byaruhanga, O; Ceja, FG; Chelebieva, S; Conrad, MD; Cooper, RA; Duvalsaint, M; Katairo, T; Legac, J; Nsobya, SL; Okitwi, M; Orena, S; Rasmussen, SA; Rosenthal, PJ; Tumwebaze, PK | 1 |
| Corry, B; Martin, RE; Richards, SN; Shafik, SH | 1 |
| Abuaku, B; Afrane, Y; Amoah, LE; Cui, L; Duah-Quashie, NO; Duan, M; Huang, Y; Li, X; Pan, M; Qin, Y; Sun, K; Wang, X; Yang, Q; Yang, Z; Zeng, W; Zhao, H; Zhao, W; Zhou, L; Zhu, W | 1 |
| Amambua-Ngwa, A; Dugassa, S; Golassa, L; Jawara, A; Oboh, M; Oriero, E; Tadele, G | 1 |
8 review(s) available for chloroquine and lumefantrine
| Article | Year |
|---|---|
Recent advances in malaria drug discovery.
Topics: Animals; Antimalarials; Drug Discovery; Humans; Liver; Liver Transplantation; Malaria; Molecular Structure | 2013 |
Current progress in antimalarial pharmacotherapy and multi-target drug discovery.
Topics: Animals; Antimalarials; Artemisinins; Drug Discovery; Drug Resistance; Humans; Malaria; Molecular Structure; Paclitaxel; Quinolines | 2020 |
[Malaria: prophylaxis, treatment, stand-by medication. A single mosquito bite suffices].
Topics: Adult; Antimalarials; Artemether; Artemisinins; Atovaquone; Chloroquine; Climate; Doxycycline; Drug Therapy, Combination; Ethanolamines; Female; Fluorenes; Humans; Lumefantrine; Malaria; Male; Mefloquine; Naphthoquinones; Pregnancy; Proguanil; Risk Factors; Self Medication; Sesquiterpenes; Time Factors; Travel | 2004 |
Malaria: uncomplicated, caused by Plasmodium falciparum.
Topics: Amodiaquine; Antimalarials; Artemether; Artemisinins; Artesunate; Chloroquine; Dapsone; Drug Combinations; Drug Therapy, Combination; Ethanolamines; Fluorenes; Humans; Lumefantrine; Malaria, Falciparum; Mefloquine; Proguanil; Pyrimethamine; Sesquiterpenes; Sulfadoxine | 2005 |
Pharmacokinetics of antimalarials in pregnancy: a systematic review.
Topics: Anti-Bacterial Agents; Antimalarials; Artemisinins; Atovaquone; Chloroquine; Drug Therapy, Combination; Ethanolamines; Female; Fluorenes; Humans; Lumefantrine; Malaria; Mefloquine; Pregnancy; Pregnancy Complications, Parasitic; Proguanil; Pyrimethamine; Quinine; Sulfadoxine | 2011 |
Update on the in vivo tolerance and in vitro reduced susceptibility to the antimalarial lumefantrine.
Topics: Antimalarials; Asia, Southeastern; Chloroquine; Drug Resistance; Drug Tolerance; Ethanolamines; Fluorenes; Genotype; Humans; Lumefantrine; Malaria; Parasitic Sensitivity Tests; Plasmodium | 2012 |
Monitoring antimalarial drug efficacy in the Greater Mekong Subregion: an overview of in vivo results from 2008 to 2010.
Topics: Antimalarials; Artemether; Artemisinins; Artesunate; Asia, Southeastern; Chloroquine; Directly Observed Therapy; Drug Resistance; Drug Therapy, Combination; Ethanolamines; Fluorenes; Humans; Lumefantrine; Malaria, Falciparum; Malaria, Vivax; Mefloquine; Parasitemia; Quinolines | 2013 |
pfmdr1 (Plasmodium falciparum multidrug drug resistance gene 1): a pivotal factor in malaria resistance to artemisinin combination therapies.
Topics: Aminoquinolines; Antimalarials; Artemisinins; Chloroquine; Drug Resistance; Drug Therapy, Combination; Ethanolamines; Fluorenes; Gene Expression Regulation; Humans; Lumefantrine; Malaria, Falciparum; Multidrug Resistance-Associated Proteins; Parasitic Sensitivity Tests; Plasmodium falciparum; Polymorphism, Genetic | 2017 |
12 trial(s) available for chloroquine and lumefantrine
| Article | Year |
|---|---|
In vitro sensitivities of Plasmodium falciparum to different antimalarial drugs in Uganda.
Topics: Antimalarials; Child; Child, Preschool; Cohort Studies; Drug Resistance; Humans; Malaria, Falciparum; Membrane Transport Proteins; Multidrug Resistance-Associated Proteins; Parasitic Sensitivity Tests; Plasmodium falciparum; Polymorphism, Genetic; Protozoan Proteins; Treatment Outcome; Uganda | 2010 |
Efficacy and safety of CGP 56697 (artemether and benflumetol) compared with chloroquine to treat acute falciparum malaria in Tanzanian children aged 1-5 years.
Topics: Acute Disease; Administration, Oral; Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Artemisinins; Child, Preschool; Chloroquine; Drug Administration Schedule; Drug Combinations; Ethanolamines; Female; Fluorenes; Humans; Infant; Lumefantrine; Malaria, Falciparum; Male; Sesquiterpenes; Tanzania; Treatment Outcome | 1998 |
Randomized comparison of chloroquine plus sulfadoxine-pyrimethamine versus artesunate plus mefloquine versus artemether-lumefantrine in the treatment of uncomplicated falciparum malaria in the Lao People's Democratic Republic.
Topics: Adolescent; Adult; Antimalarials; Artemether; Artemisinins; Artesunate; Child; Child, Preschool; Chloroquine; Drug Combinations; Drug Therapy, Combination; Ethanolamines; Female; Fluorenes; Humans; Infant; Laos; Lumefantrine; Malaria, Falciparum; Male; Mefloquine; Pyrimethamine; Sesquiterpenes; Sulfadoxine | 2004 |
In-vitro sensitivity testing of Plasmodium vivax: response to lumefantrine and chloroquine in northwestern Thailand.
Topics: Adolescent; Adult; Animals; Antimalarials; Cell Proliferation; Child; Child, Preschool; Chloroquine; Dose-Response Relationship, Drug; Drug Combinations; Drug Evaluation; Ethanolamines; Female; Fluorenes; Humans; Lethal Dose 50; Lumefantrine; Malaria, Vivax; Male; Middle Aged; Parasitic Sensitivity Tests; Plasmodium vivax; Species Specificity; Thailand; Treatment Outcome | 2003 |
Efficacy of chloroquine + sulfadoxine--pyrimethamine, mefloquine + artesunate and artemether + lumefantrine combination therapies to treat Plasmodium falciparum malaria in the Chittagong Hill Tracts, Bangladesh.
Topics: Adolescent; Antimalarials; Artemether; Artemisinins; Artesunate; Bangladesh; Child; Child, Preschool; Chloroquine; Drug Combinations; Drug Therapy, Combination; Ethanolamines; Female; Fluorenes; Humans; Infant; Lumefantrine; Malaria, Falciparum; Male; Mefloquine; Pyrimethamine; Sesquiterpenes; Sulfadoxine; Treatment Outcome | 2005 |
[Surveillance of falciparum malaria susceptibility to antimalarial drugs and policy change in the Comoros].
Topics: Animals; Antimalarials; Artemether; Artemisinins; Child; Child, Preschool; Chloroquine; Clinical Protocols; Comoros; Consensus Development Conferences as Topic; Drug Combinations; Drug Resistance; Ethanolamines; Female; Fluorenes; Genotype; Health Policy; Humans; Infant; Lumefantrine; Malaria, Falciparum; Male; Plasmodium falciparum; Practice Guidelines as Topic; Public Health Administration; Recurrence; World Health Organization | 2007 |
Clinical efficacy of chloroquine versus artemether-lumefantrine for Plasmodium vivax treatment in Thailand.
Topics: Adolescent; Aged; Animals; Antimalarials; Artemether; Artemisinins; Chloroquine; Drug Therapy, Combination; Ethanolamines; Female; Fluorenes; Humans; Lumefantrine; Malaria, Vivax; Male; Middle Aged; Parasitemia; Plasmodium vivax; Primaquine; Thailand; Treatment Outcome | 2007 |
A trial of combination antimalarial therapies in children from Papua New Guinea.
Topics: Antimalarials; Artemether; Artemisinins; Artesunate; Child, Preschool; Chloroquine; Drug Therapy, Combination; Ethanolamines; Female; Fluorenes; Humans; Infant; Kaplan-Meier Estimate; Lumefantrine; Malaria, Falciparum; Malaria, Vivax; Male; Proportional Hazards Models; Pyrimethamine; Quinolines; Recurrence; Sulfadoxine | 2008 |
Therapeutic efficacy and effect on gametocyte carriage of an artemisinin and a non-based combination treatment in children with uncomplicated P. falciparum malaria, living in an area with high-level chloroquine resistance.
Topics: Amodiaquine; Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Artemisinins; Child, Preschool; Chloroquine; Drug Combinations; Drug Resistance; Drug Therapy, Combination; Ethanolamines; Female; Fluorenes; Follow-Up Studies; Gametogenesis; Humans; Infant; Lumefantrine; Malaria, Falciparum; Male; Nigeria; Plasmodium falciparum; Polymerase Chain Reaction; Pyrimethamine; Sulfalene; Treatment Outcome | 2010 |
In vivo efficacy of artemether-lumefantrine and chloroquine against Plasmodium vivax: a randomized open label trial in central Ethiopia.
Topics: Adolescent; Adult; Aged; Antimalarials; Artemether; Artemisinins; Child; Child, Preschool; Chloroquine; Ethanolamines; Ethiopia; Female; Fluorenes; Genotype; Humans; Infant; Lumefantrine; Malaria, Vivax; Male; Middle Aged; Parasitemia; Plasmodium vivax; Primaquine; Prospective Studies; Survival Analysis; Treatment Outcome; Young Adult | 2013 |
Temporal and seasonal changes of genetic polymorphisms associated with altered drug susceptibility to chloroquine, lumefantrine, and quinine in Guinea-Bissau between 2003 and 2012.
Topics: Adolescent; Antimalarials; Child; Child, Preschool; Chloroquine; Ethanolamines; Female; Fluorenes; Guinea-Bissau; Humans; Lumefantrine; Malaria, Falciparum; Male; Quinine | 2015 |
Changing Antimalarial Drug Sensitivities in Uganda.
Topics: Adolescent; Amodiaquine; Antimalarials; Artemisinins; Aspartic Acid Endopeptidases; Child; Child, Preschool; Chloroquine; Drug Resistance; Ethanolamines; Female; Fluorenes; Gene Expression; Humans; Infant; Inhibitory Concentration 50; Lumefantrine; Malaria, Falciparum; Male; Mefloquine; Membrane Transport Proteins; Multidrug Resistance-Associated Proteins; Mutation; Parasitic Sensitivity Tests; Plasmodium falciparum; Protozoan Proteins; Quinolines; Uganda; Young Adult | 2017 |
59 other study(ies) available for chloroquine and lumefantrine
| Article | Year |
|---|---|
Structure-activity relationships of novel anti-malarial agents. Part 3: N-(4-acylamino-3-benzoylphenyl)-4-propoxycinnamic acid amides.
Topics: Amides; Animals; Antimalarials; Benzophenones; Cinnamates; Humans; Inhibitory Concentration 50; Phenylacetates; Plasmodium falciparum; Structure-Activity Relationship | 2002 |
Structure-activity relationships of novel anti-malarial agents: part 5. N-(4-acylamino-3-benzoylphenyl)-[5-(4-nitrophenyl)-2-furyl]acrylic acid amides.
Topics: Acrylates; Animals; Antimalarials; Drug Resistance, Multiple; Erythrocytes; Furans; Humans; Indicators and Reagents; Plasmodium falciparum; Structure-Activity Relationship | 2003 |
Structure-activity relationships of novel anti-malarial agents. Part 6: N-(4-arylpropionylamino-3-benzoylphenyl)-[5-(4-nitrophenyl)-2-furyl]acrylic acid amides.
Topics: Amides; Animals; Antimalarials; Benzophenones; Furans; Nitro Compounds; Plasmodium falciparum; Stereoisomerism; Structure-Activity Relationship | 2003 |
Structure-activity relationships of novel anti-malarial agents. Part 7: N-(3-benzoyl-4-tolylacetylaminophenyl)-3-(5-aryl-2-furyl)acrylic acid amides with polar moieties.
Topics: Acrylates; Alkyl and Aryl Transferases; Amides; Animals; Antimalarials; Enzyme Inhibitors; Farnesyltranstransferase; Furans; Hydrogen Bonding; Indicators and Reagents; Plasmodium falciparum; Structure-Activity Relationship | 2003 |
The pharmacophore hypotheses of I(Kr) potassium channel blockers: novel class III antiarrhythmic agents.
Topics: Anti-Arrhythmia Agents; Models, Biological; Models, Molecular; Potassium Channel Blockers; Potassium Channels; Quantitative Structure-Activity Relationship; Technology, Pharmaceutical | 2004 |
Determinants of in vitro drug susceptibility testing of Plasmodium vivax.
Topics: Animals; Antimalarials; Chloroquine; Humans; Inhibitory Concentration 50; Life Cycle Stages; Parasitic Sensitivity Tests; Plasmodium falciparum; Plasmodium vivax; Schizonts; Time Factors | 2008 |
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.
Topics: Animals; Antimalarials; Cluster Analysis; Computational Biology; Drug Evaluation, Preclinical; Drug Resistance; Folic Acid Antagonists; Malaria; Models, Molecular; Parasites; Plasmodium falciparum; Reproducibility of Results; Structure-Activity Relationship; Tetrahydrofolate Dehydrogenase | 2008 |
In vivo and in vitro efficacy of amodiaquine monotherapy for treatment of infection by chloroquine-resistant Plasmodium vivax.
Topics: Adolescent; Age Distribution; Amodiaquine; Animals; Antimalarials; Chloroquine; Confidence Intervals; Drug Resistance; Drug Tolerance; Female; Follow-Up Studies; Humans; Inhibitory Concentration 50; Male; Outpatients; Parasitemia; Plasmodium vivax; Prospective Studies; Recurrence; Rural Health; Time Factors; Treatment Failure; Treatment Outcome | 2009 |
Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malaria.
Topics: Animals; Antimalarials; Atorvastatin; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Plasmodium falciparum; Pyrroles | 2009 |
In vitro chemosensitization of Plasmodium falciparum to antimalarials by verapamil and probenecid.
Topics: Adjuvants, Pharmaceutic; Animals; Antimalarials; Parasitic Sensitivity Tests; Plasmodium falciparum; Probenecid; Verapamil | 2009 |
In vitro activities of piperaquine, lumefantrine, and dihydroartemisinin in Kenyan Plasmodium falciparum isolates and polymorphisms in pfcrt and pfmdr1.
Topics: Animals; Antimalarials; Artemisinins; Ethanolamines; Fluorenes; Genotype; Humans; Lumefantrine; Malaria, Falciparum; Membrane Transport Proteins; Microbial Sensitivity Tests; Multidrug Resistance-Associated Proteins; Plasmodium falciparum; Polymorphism, Genetic; Protozoan Proteins; Quinolines | 2009 |
In vitro activities of quinine and other antimalarials and pfnhe polymorphisms in Plasmodium isolates from Kenya.
Topics: Amino Acid Sequence; Animals; Antimalarials; Drug Resistance; Humans; Kenya; Mefloquine; Membrane Transport Proteins; Molecular Sequence Data; Multidrug Resistance-Associated Proteins; Parasitic Sensitivity Tests; Phenanthrenes; Plasmodium falciparum; Polymorphism, Genetic; Protozoan Proteins; Quinine; Sequence Analysis, DNA; Sodium-Hydrogen Exchangers | 2010 |
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.
Topics: Computer Simulation; Ether-A-Go-Go Potassium Channels; Humans; Molecular Structure; Organic Chemicals; Quantitative Structure-Activity Relationship | 2011 |
Synthesis and antimalarial evaluation of novel isocryptolepine derivatives.
Topics: 3T3 Cells; Animals; Antimalarials; Chloroquine; Humans; Indole Alkaloids; Malaria, Falciparum; Mice; Plasmodium falciparum; Quinolines; Structure-Activity Relationship | 2011 |
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.
Topics: Animals; Antimalarials; Cell Line, Tumor; Drug Discovery; Drug Evaluation, Preclinical; Drug Resistance; Erythrocytes; Humans; Imidazoles; Liver; Malaria; Mice; Mice, Inbred BALB C; Molecular Structure; Piperazines; Plasmodium; Plasmodium berghei; Plasmodium falciparum; Plasmodium yoelii; Polymorphism, Single Nucleotide; Protozoan Proteins; Random Allocation; Small Molecule Libraries; Sporozoites | 2011 |
Synthesis and evaluation of the antiplasmodial activity of novel indeno[2,1-c]quinoline derivatives.
Topics: Antimalarials; Cell Line; Cell Survival; Chloroquine; Drug Resistance; Humans; Plasmodium falciparum; Quinolines; Structure-Activity Relationship | 2014 |
3-Hydroxy-N'-arylidenepropanehydrazonamides with Halo-Substituted Phenanthrene Scaffolds Cure P. berghei Infected Mice When Administered Perorally.
Topics: Amides; Animals; Antimalarials; Hep G2 Cells; Humans; Hydrazones; Malaria; Mice; Phenanthrenes; Plasmodium berghei; Stereoisomerism; Structure-Activity Relationship | 2017 |
Discovery and Structural Optimization of Acridones as Broad-Spectrum Antimalarials.
Topics: Acridones; Animals; Antimalarials; Disease Models, Animal; Drug Discovery; Hep G2 Cells; Humans; Malaria; Mice; Plasmodium; Species Specificity; Structure-Activity Relationship | 2019 |
Lead Optimization of Second-Generation Acridones as Broad-Spectrum Antimalarials.
Topics: Acridones; Administration, Oral; Animals; Antimalarials; Cell Survival; Disease Models, Animal; Female; Half-Life; Hep G2 Cells; Humans; Life Cycle Stages; Malaria; Male; Mice; Mice, Inbred C57BL; Plasmodium falciparum; Structure-Activity Relationship | 2020 |
Synergism of benflumetol and artemether in Plasmodium falciparum.
Topics: Animals; Antimalarials; Artemether; Artemisinins; Chloroquine; Culture Media; Drug Resistance, Multiple; Drug Synergism; Ethanolamines; Fluorenes; Inhibitory Concentration 50; Lumefantrine; Plasmodium falciparum; Pyrimethamine; Sesquiterpenes | 1999 |
[Malaria: a medical and economic problem].
Topics: Anti-Infective Agents; Antimalarials; Artemisinins; Atovaquone; Chloroquine; Drug Combinations; Drug Resistance; Ethanolamines; Fluorenes; Health Care Costs; Humans; Lumefantrine; Malaria, Falciparum; Naphthoquinones; Proguanil; Sesquiterpenes; Survival Rate; World Health Organization | 2006 |
From chloroquine to artemisinin-based combination therapy: the Sudanese experience.
Topics: Antimalarials; Artemether; Artemisinins; Artesunate; Chloroquine; Drug Combinations; Drug Therapy, Combination; Ethanolamines; Fluorenes; Health Policy; Humans; Lumefantrine; Malaria, Falciparum; Product Surveillance, Postmarketing; Pyrimethamine; Sesquiterpenes; Sudan; Sulfadoxine; Time Factors | 2006 |
In vitro antimalarial drug susceptibility and pfcrt mutation among fresh Plasmodium falciparum isolates from the Lao PDR (Laos).
Topics: Adolescent; Adult; Animals; Antimalarials; Artemisinins; Artesunate; Child; Child, Preschool; Chloroquine; DNA, Protozoan; Drug Resistance; Ethanolamines; Female; Fluorenes; Humans; Inhibitory Concentration 50; Laos; Lumefantrine; Malaria, Falciparum; Male; Mefloquine; Membrane Transport Proteins; Middle Aged; Plasmodium falciparum; Point Mutation; Polymerase Chain Reaction; Protozoan Proteins; Sesquiterpenes | 2007 |
Pharmacologic advances in the global control and treatment of malaria: combination therapy and resistance.
Topics: Amodiaquine; Antimalarials; Artemether; Artemisinins; Artesunate; Chloroquine; Dapsone; Drug Design; Drug Resistance; Drug Therapy, Combination; Ethanolamines; Female; Fluorenes; Global Health; Half-Life; Humans; Lumefantrine; Malaria; Mefloquine; Pregnancy; Pregnancy Complications, Infectious; Proguanil; Pyrimethamine; Quinine; Sesquiterpenes; Sulfadoxine | 2007 |
From chloroquine to artemether-lumefantrine: the process of drug policy change in Zambia.
Topics: Antimalarials; Artemisinins; Chloroquine; Drug Therapy, Combination; Ethanolamines; Fluorenes; Health Planning Guidelines; Health Policy; Humans; Lumefantrine; Malaria; Zambia | 2008 |
Malariological baseline survey and in vitro antimalarial drug resistance in Gulu district, Northern Uganda.
Topics: Adolescent; Adult; Amodiaquine; Animals; Antimalarials; Artemisinins; Child; Child, Preschool; Chloroquine; Cross-Sectional Studies; Developing Countries; Drug Resistance; Drug Therapy, Combination; Endemic Diseases; Ethanolamines; Evidence-Based Medicine; Female; Fluorenes; Health Surveys; Humans; Incidence; Infant; Lumefantrine; Malaria, Falciparum; Male; Parasitic Sensitivity Tests; Plasmodium falciparum; Refugees; Uganda; Young Adult | 2008 |
Plasmodium berghei ANKA: selection of resistance to piperaquine and lumefantrine in a mouse model.
Topics: Amodiaquine; Animals; Antimalarials; Artemisinins; Chloroquine; Disease Models, Animal; Drug Resistance; Ethanolamines; Female; Fluorenes; Lumefantrine; Malaria; Male; Mice; Parasitemia; Plasmodium berghei; Quinolines; Serial Passage | 2009 |
Plasmodium berghei K173: selection of resistance to naphthoquine in a mouse model.
Topics: Animals; Antimalarials; Artemisinins; Chloroquine; Dose-Response Relationship, Drug; Drug Resistance; Ethanolamines; Fluorenes; Lumefantrine; Malaria; Male; Mice; Naphthoquinones; Plasmodium berghei; Pyrimethamine; Random Allocation | 2011 |
In vitro activity of Proveblue (methylene blue) on Plasmodium falciparum strains resistant to standard antimalarial drugs.
Topics: Amodiaquine; Antimalarials; Chloroquine; Ethanolamines; Fluorenes; Inhibitory Concentration 50; Lumefantrine; Mefloquine; Methylene Blue; Plasmodium falciparum; Polymorphism, Genetic; Protozoan Proteins; Quinine | 2011 |
Severe Plasmodium knowlesi malaria in a tertiary care hospital, Sabah, Malaysia.
Topics: Acute Kidney Injury; Adult; Antimalarials; Artemether; Artemisinins; Artesunate; Chloroquine; Ethanolamines; Female; Fluorenes; Hospitals, Urban; Humans; Lumefantrine; Malaria; Malaysia; Microscopy; Middle Aged; Parasitemia; Patient Selection; Plasmodium knowlesi; Polymerase Chain Reaction; Quinine; Respiratory Distress Syndrome; Severity of Illness Index; Shock; Survival Rate | 2011 |
Ex vivo responses of Plasmodium falciparum clinical isolates to conventional and new antimalarial drugs in Niger.
Topics: Amodiaquine; Antimalarials; Artemisinins; Chloroquine; Drug Resistance; Ethanolamines; Fluorenes; Humans; Lumefantrine; Malaria, Falciparum; Naphthyridines; Niger; Parasitic Sensitivity Tests; Plasmodium falciparum; Quinolines | 2013 |
The role of Pfmdr1 and Pfcrt in changing chloroquine, amodiaquine, mefloquine and lumefantrine susceptibility in western-Kenya P. falciparum samples during 2008-2011.
Topics: Amodiaquine; Antimalarials; Chloroquine; DNA, Protozoan; Drug Resistance; Ethanolamines; Fluorenes; Haplotypes; Humans; Inhibitory Concentration 50; Kenya; Lumefantrine; Malaria, Falciparum; Mefloquine; Membrane Transport Proteins; Multidrug Resistance-Associated Proteins; Plasmodium falciparum; Polymorphism, Single Nucleotide; Protozoan Proteins; Retrospective Studies | 2013 |
Nonlinear mixed-effects modelling of in vitro drug susceptibility and molecular correlates of multidrug resistant Plasmodium falciparum.
Topics: Antimalarials; Artemisinins; Artesunate; Chloroquine; Ethanolamines; Fluorenes; Lumefantrine; Mefloquine; Models, Statistical; Multidrug Resistance-Associated Proteins; Plasmodium falciparum; Polymorphism, Genetic; Polymorphism, Single Nucleotide; Protozoan Proteins | 2013 |
Repeat polymorphisms in the low-complexity regions of Plasmodium falciparum ABC transporters and associations with in vitro antimalarial responses.
Topics: Amino Acid Motifs; Antimalarials; Artemisinins; Asparagine; Aspartic Acid; Chloroquine; Drug Resistance; Ethanolamines; Fluorenes; Gene Expression; Genome, Protozoan; Lumefantrine; Mefloquine; Molecular Sequence Data; Multidrug Resistance-Associated Proteins; Parasitic Sensitivity Tests; Plasmodium falciparum; Polymorphism, Genetic; Protozoan Proteins; Quinine | 2013 |
Plasmodium falciparum multidrug resistance protein 1 (pfmrp1) gene and its association with in vitro drug susceptibility of parasite isolates from north-east Myanmar.
Topics: Antimalarials; ATP Binding Cassette Transporter, Subfamily B, Member 1; Base Sequence; Chloroquine; Drug Resistance; Ethanolamines; Fluorenes; Geography; Humans; Lumefantrine; Malaria, Falciparum; Mefloquine; Multidrug Resistance-Associated Proteins; Mutation; Myanmar; Naphthyridines; Parasitic Sensitivity Tests; Plasmodium falciparum; Polymorphism, Single Nucleotide; Selection, Genetic; Sequence Analysis, DNA | 2014 |
Polymorphisms in Plasmodium falciparum chloroquine resistance transporter and multidrug resistance 1 genes: parasite risk factors that affect treatment outcomes for P. falciparum malaria after artemether-lumefantrine and artesunate-amodiaquine.
Topics: Amino Acid Substitution; Amodiaquine; Antimalarials; Artemether; Artemisinins; Child; Child, Preschool; Chloroquine; Datasets as Topic; Drug Combinations; Drug Resistance; Drug Therapy, Combination; Ethanolamines; Fluorenes; Genetic Markers; Genotype; Humans; Infant; Kaplan-Meier Estimate; Lumefantrine; Malaria, Falciparum; Membrane Transport Proteins; Multidrug Resistance-Associated Proteins; Plasmodium falciparum; Polymorphism, Genetic; Protozoan Proteins; Risk Factors | 2014 |
Role of Pfmdr1 in in vitro Plasmodium falciparum susceptibility to chloroquine, quinine, monodesethylamodiaquine, mefloquine, lumefantrine, and dihydroartemisinin.
Topics: Adult; Amodiaquine; Antimalarials; Artemisinins; Biological Transport; Child; Chloroquine; Drug Resistance; Erythrocytes; Ethanolamines; Female; Fluorenes; Gene Expression; Haplotypes; Humans; Inhibitory Concentration 50; Lumefantrine; Malaria, Falciparum; Male; Mefloquine; Multidrug Resistance-Associated Proteins; Parasitic Sensitivity Tests; Plasmodium falciparum; Polymorphism, Single Nucleotide; Quinine; Senegal | 2014 |
Impact of antimalarial treatment and chemoprevention on the drug sensitivity of malaria parasites isolated from ugandan children.
Topics: Amodiaquine; Antimalarials; Artemisinins; Child, Preschool; Chloroquine; Clinical Trials as Topic; Ethanolamines; Fluorenes; Humans; Infant; Lumefantrine; Membrane Transport Proteins; Multidrug Resistance-Associated Proteins; Parasitic Sensitivity Tests; Plasmodium falciparum; Polymorphism, Genetic; Protozoan Proteins; Quinine; Quinolines; Uganda | 2015 |
In Vitro and Molecular Surveillance for Antimalarial Drug Resistance in Plasmodium falciparum Parasites in Western Kenya Reveals Sustained Artemisinin Sensitivity and Increased Chloroquine Sensitivity.
Topics: Alleles; Amodiaquine; Animals; Antimalarials; Artemisinins; Child; Child, Preschool; Chloroquine; Drug Resistance; Epidemiological Monitoring; Ethanolamines; Fluorenes; Gene Dosage; Gene Expression; Genotype; Humans; Kenya; Lumefantrine; Malaria, Falciparum; Mefloquine; Membrane Transport Proteins; Multidrug Resistance-Associated Proteins; Parasitic Sensitivity Tests; Plasmodium falciparum; Polymorphism, Genetic; Protozoan Proteins | 2015 |
In Vitro Activities of Primaquine-Schizonticide Combinations on Asexual Blood Stages and Gametocytes of Plasmodium falciparum.
Topics: Antimalarials; Benzothiazoles; Chloroquine; Diamines; Drug Combinations; Drug Interactions; Erythrocytes; Ethanolamines; Flow Cytometry; Fluorenes; Humans; Lumefantrine; Mefloquine; Organic Chemicals; Parasitic Sensitivity Tests; Plasmodium falciparum; Primaquine; Quinolines; Sporozoites; Trophozoites | 2015 |
In vivo efficacy and bioavailability of lumefantrine: Evaluating the application of Pheroid technology.
Topics: Administration, Oral; Animals; Antimalarials; Biological Availability; Chemistry, Pharmaceutical; Chloroquine; Disease Models, Animal; Drug Stability; Ethanolamines; Fluorenes; Food-Drug Interactions; Lumefantrine; Malaria; Male; Mice; Mice, Inbred C57BL; Solubility; Technology, Pharmaceutical | 2015 |
Absence of Association between Polymorphisms in the RING E3 Ubiquitin Protein Ligase Gene and Ex Vivo Susceptibility to Conventional Antimalarial Drugs in Plasmodium falciparum Isolates from Dakar, Senegal.
Topics: Antimalarials; Artemisinins; Artesunate; Chloroquine; Doxycycline; Ethanolamines; Fluorenes; Lumefantrine; Mefloquine; Naphthyridines; Plasmodium falciparum; Polymorphism, Genetic; Quinine; Quinolines; Senegal; Ubiquitin-Protein Ligases | 2016 |
Malaria research and its influence on anti-malarial drug policy in Malawi: a case study.
Topics: Antimalarials; Artemether; Artemisinins; Biomedical Research; Chloroquine; Drug Combinations; Drug Resistance; Ethanolamines; Evidence-Based Medicine; Fluorenes; Health Policy; Humans; Lumefantrine; Malaria; Malaria, Falciparum; Malawi; Plasmodium falciparum; Pyrimethamine; Sulfadoxine; Treatment Outcome | 2016 |
Association between Polymorphisms in the Pf
Topics: Amodiaquine; Antimalarials; Artemisinins; Artesunate; Asparagine; ATP-Binding Cassette Transporters; Chloroquine; Doxycycline; Drug Resistance; Ethanolamines; Fluorenes; Gene Expression; Humans; Inhibitory Concentration 50; Lumefantrine; Malaria, Falciparum; Mefloquine; Naphthyridines; Plasmodium falciparum; Polymorphism, Genetic; Protein Isoforms; Protozoan Proteins; Quinine; Quinolines; Repetitive Sequences, Amino Acid; Senegal | 2017 |
Sustained
Topics: Amodiaquine; Antimalarials; Artemisinins; Chloroquine; Drug Resistance; Drug Therapy, Combination; Ethanolamines; Fluorenes; Gambia; Humans; Lumefantrine; Malaria, Falciparum; Membrane Transport Proteins; Microsatellite Repeats; Multidrug Resistance-Associated Proteins; Parasitic Sensitivity Tests; Plasmodium falciparum; Polymorphism, Single Nucleotide; Protozoan Proteins; Quinolines | 2017 |
In vitro anti-malarial interaction and gametocytocidal activity of cryptolepine.
Topics: Alkaloids; Antimalarials; Chloroquine; Ethanolamines; Fluorenes; Gametogenesis; Ghana; Humans; Indole Alkaloids; Life Cycle Stages; Lumefantrine; Malaria; Malaria, Falciparum; Mefloquine; Plant Extracts; Plasmodium falciparum; Quinolines | 2017 |
Topics: Anti-Bacterial Agents; Antimalarials; Artemether; Artemisinins; Atovaquone; Azithromycin; Chloroquine; Doxycycline; Ethanolamines; Fluorenes; Humans; India; Lumefantrine; Malaria, Falciparum; Mefloquine; Plasmodium falciparum; Quinine; Quinolines | 2017 |
Longitudinal surveillance of drug resistance in Plasmodium falciparum isolates from the China-Myanmar border reveals persistent circulation of multidrug resistant parasites.
Topics: Antimalarials; Artemisinins; China; Chloroquine; Drug Resistance, Multiple; Epidemiological Monitoring; Genotype; Humans; In Vitro Techniques; Inhibitory Concentration 50; Lumefantrine; Malaria, Falciparum; Multidrug Resistance-Associated Proteins; Mutation; Myanmar; Plasmodium falciparum; Protozoan Proteins | 2018 |
Spatio-temporal distribution of PfMDR1 polymorphism among uncomplicated Plasmodium falciparum malaria cases along international border of north east India.
Topics: Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Bangladesh; Chloroquine; Drug Combinations; Drug Resistance; Erythrocytes; Gene Expression; Haplotypes; Humans; India; Lumefantrine; Malaria, Falciparum; Multidrug Resistance-Associated Proteins; Myanmar; Phylogeny; Phylogeography; Plasmodium falciparum; Polymorphism, Single Nucleotide; Pyrimethamine; Sulfadoxine | 2018 |
Lack of significant recovery of chloroquine sensitivity in Plasmodium falciparum parasites following discontinuance of chloroquine use in Papua New Guinea.
Topics: Adolescent; Adult; Antimalarials; Child; Child, Preschool; Chloroquine; Cross-Sectional Studies; Drug Resistance; Drug Utilization; Female; Genotype; Genotyping Techniques; Humans; Infant; Infant, Newborn; Inhibitory Concentration 50; Lumefantrine; Malaria, Falciparum; Male; Membrane Transport Proteins; Middle Aged; Multidrug Resistance-Associated Proteins; Papua New Guinea; Parasitic Sensitivity Tests; Plasmodium falciparum; Protozoan Proteins; Young Adult | 2018 |
Changing Molecular Markers of Antimalarial Drug Sensitivity across Uganda.
Topics: Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Aspartic Acid Endopeptidases; Child; Chloroquine; Drug Resistance; Folic Acid Antagonists; Humans; Lumefantrine; Malaria, Falciparum; Membrane Transport Proteins; Multidrug Resistance-Associated Proteins; Plasmodium falciparum; Polymorphism, Single Nucleotide; Protozoan Proteins; Quinolines; Uganda | 2019 |
Evolution of Plasmodium falciparum drug resistance genes following artemisinin combination therapy in Sudan.
Topics: Amodiaquine; Antimalarials; Artemether; Artemisinins; Artesunate; Chloroquine; DNA, Protozoan; Drug Resistance; Drug Therapy, Combination; Genetic Markers; Genotype; Humans; Lumefantrine; Malaria, Falciparum; Mutation; Plasmodium falciparum; Polymorphism, Genetic; Protozoan Proteins; Pyrimethamine; Sudan; Sulfadoxine | 2019 |
Ex-vivo Sensitivity of Plasmodium falciparum to Common Anti-malarial Drugs: The Case of Kéniéroba, a Malaria Endemic Village in Mali.
Topics: Adolescent; Amodiaquine; Antimalarials; Artemisinins; Child; Child, Preschool; Chloroquine; Drug Resistance; Endemic Diseases; Humans; Infant; Inhibitory Concentration 50; Lumefantrine; Malaria, Falciparum; Mali; Mefloquine; Plasmodium falciparum; Quinine; Quinolines | 2020 |
Ex vivo susceptibility of Plasmodium falciparum to antimalarial drugs in Northern Uganda.
Topics: Amodiaquine; Antimalarials; Artemisinins; Chloroquine; Drug Resistance; Lumefantrine; Mefloquine; Plasmodium falciparum; Quinine; Uganda | 2021 |
Balanced impacts of fitness and drug pressure on the evolution of PfMDR1 polymorphisms in Plasmodium falciparum.
Topics: Antimalarials; Chloroquine; Genetic Fitness; Haplotypes; Lumefantrine; Multidrug Resistance-Associated Proteins; Mutation; Plasmodium falciparum; Quinolines | 2021 |
Drug susceptibility of
Topics: Antimalarials; Chloroquine; Genotype; Humans; Longitudinal Studies; Lumefantrine; Malaria, Falciparum; Phenotype; Plasmodium falciparum; Prospective Studies; Uganda | 2021 |
Mechanistic basis for multidrug resistance and collateral drug sensitivity conferred to the malaria parasite by polymorphisms in PfMDR1 and PfCRT.
Topics: Animals; Antimalarials; Chloroquine; Drug Resistance; Drug Resistance, Multiple; Lumefantrine; Malaria, Falciparum; Mefloquine; Multidrug Resistance-Associated Proteins; Parasites; Plasmodium falciparum; Protein Isoforms; Protozoan Proteins | 2022 |
Topics: Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Chloroquine; Ghana; Humans; Lumefantrine; Malaria, Falciparum; Plasmodium falciparum; Protozoan Proteins; Pyrimethamine | 2022 |
Clinical isolates of uncomplicated falciparum malaria from high and low malaria transmission areas show distinct pfcrt and pfmdr1 polymorphisms in western Ethiopia.
Topics: Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Chloroquine; Drug Resistance; Ethiopia; Humans; Lumefantrine; Malaria; Malaria, Falciparum; Multidrug Resistance-Associated Proteins; Plasmodium falciparum; Polymorphism, Single Nucleotide; Protozoan Proteins | 2023 |